CER Daily Newsfeed

GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin

(1/6, Julia Bonavitacola, The American Journal of Managed Care) reports “...Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to offer promising results in a variety of specialties, including cardiology and obesity, with new results presented during the press briefing for the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium offering up a new area of interest for use of this treatment.” Full

Thermo Fisher Launches Obesity Registry to Track Real-World Treatment Outcomes

(1/7, Brian Buntz, Drug Discovery & Development) reports “...The PPD CorEvitas Obesity Registry will collect longitudinal data from both clinicians and patients. It will track how therapies are used in practice, how long patients remain on treatment and what safety or tolerability concerns emerge over time. The company says the registry will also capture patient-reported outcomes across a range of care settings.” Full

Public Unclear What CDC-Backed Shared Decision-Making Is

(1/6, Sara Heath, TechTarget) reports “...Although its origins can be traced back to the 1980s, shared decision-making gained notoriety during the insurgence of value-based care and patient engagement during the 2010s. It's considered a best practice in patient–provider communication. Shared decision-making has reentered the cultural conversation as part of the CDC's work to redesign the nation's recommended childhood vaccine schedule to reflect those of other wealthy nations.” Full

England’s Innovative Medicines Fund Falls Short on Evidence, Serves As Stopgap

(1/7, Leela Barham, Pink Sheet) reports “...Products likely to be subject to evidence generation agreements under England’s Innovative Medicines Fund are those that are costly and which serve a low number of patients. Orphan drugs appear most likely to receive interim funding through the IMF.” Subscription Required